Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

STRATA Skin Sciences (SSKN) Income from Continuing Operations (2016 - 2025)

STRATA Skin Sciences' Income from Continuing Operations history spans 13 years, with the latest figure at 994000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 52.07% year-over-year to 994000.0; the TTM value through Sep 2025 reached 3975000.0, up 61.34%, while the annual FY2024 figure was 10272000.0, 5.15% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 994000.0 at STRATA Skin Sciences, up from 2575000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1230000.0 in Q4 2024 and bottomed at 3886000.0 in Q4 2023.
  • The 5-year median for Income from Continuing Operations is 1636000.0 (2025), against an average of 1505157.89.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 164.4% in 2021 before it tumbled 3138.33% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 849000.0 in 2021, then surged by 85.87% to 120000.0 in 2022, then crashed by 3138.33% to 3886000.0 in 2023, then soared by 131.65% to 1230000.0 in 2024, then plummeted by 180.81% to 994000.0 in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Income from Continuing Operations are 994000.0 (Q3 2025), 2575000.0 (Q2 2025), and 1636000.0 (Q1 2025).